



4-25-05

1FN

A receipt

CASE ON/4-32331A

EV 524612275US

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

Express Mail Label Number

April 22, 2005

Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

CARLOS GARCIA-ECHEVERRIA

INTERNATIONAL APPLICATION NO: PCT/EP03/00803

Art Unit: 1616

FILED: 27 JANUARY 2003

U.S. APPLICATION NO: 10/502,533

35 USC §371 DATE: JANUARY 20, 2005

FOR: BETA-HOMOLYSINE CONJUGATES AND THEIR USE AS
TRANSPORT ENHANCER**Mail Stop: PCT**

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

LETTER CORRECTING OFFICIAL FILING RECEIPT

Sir:

The official filing receipt received in the above-identified application erroneously lists the **Applicant(s)** information. There is only one inventor in this case. Enclosed is a copy of the title page of the International Publication WO 03/063 910 showing this to be true. Please issue a corrected filing receipt listing the applicants' information as follows:


-- Applicant(s)

Carlos Garcia-Echeverria, Basel, SWITZERLAND; --

A copy of the filing receipt with the correction noted is enclosed.

No fee is believed to be required by this request for a corrected filing receipt.

Respectfully submitted,



Lydia T. McNally
Attorney for Applicant
Reg. No. 36,214

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7898
LTM:dd
Encls.:
Date: April 21, 2005



O I P E
J U D G E
APR 22 2005
UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPL NO.	FILING OR 371 (C) DATE	ART UNIT	FIL FEE REC'D	ATTY.DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/502,533	01/20/2005	1616	1050	ON/4-32331A		16	2

CONFIRMATION NO. 7484

FILING RECEIPT



OC000000015176610

LTM

Date Mailed: 02/16/2005

001095
NOVARTIS
CORPORATE INTELLECTUAL PROPERTY
ONE HEALTH PLAZA 104/3
EAST HANOVER, NJ 07936-1080

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Olivier Loiseleur, Saint-Louis, FRANCE;
 Daniel Kaufmann, Therwil, SWITZERLAND;
 Stephan Abel, Weil am Rhein, GERMANY;
 Hans-Michael Burger, Allschwil, SWITZERLAND;
 Mark Meisenbach, Durmenach, FRANCE;
 Beat Schmitz, Allschwil, SWITZERLAND;
 Gottfried Sedelmeier, Schallstadt, GERMANY;

Carlos Garcia-Echeverria, Basel, Switzerland

Power of Attorney:

Lydia McNally--36214

Domestic Priority data as claimed by applicant


This application is a 371 of PCT/EP03/00803 01/27/2003

Foreign Applications

UNITED KINGDOM 02018810 01/28/2002
 UNITED KINGDOM 02028751 02/07/2002

Projected Publication Date: 05/26/2005

Non-Publication Request: No



Case 4-32331A

13

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
7 August 2003 (07.08.2003)

PCT

(10) International Publication Number
WO 03/063910 A2

- (51) International Patent Classification⁷: **A61K 47/48**
- (21) International Application Number: **PCT/EP03/00803**
- (22) International Filing Date: 27 January 2003 (27.01.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
0201881.0 / 28 January 2002 (28.01.2002) GB
0202875.1 / 7 February 2002 (07.02.2002) GB

(74) Agent: GROS, Florent; Novartis AG, Corporate Intellectual Property, Patent and Trademark Department, CH-4002 Basel (CH).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW.

(84) Designated States (*regional*): Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR).

(71) Applicant (*for all designated States except AT, US*): NOVARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(71) Applicant (*for AT only*): NOVARTIS PHARMA GMBH [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

(72) Inventor; and

(75) Inventor/Applicant (*for US only*): GARCIA-ECHEVERRIA, Carlos [ES/CH]; Engelgasse 126, CH-4052 Basel (CH).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 03/063910 A2

(54) Title: **β-HOMOLYSINE CONJUGATES AND THEIR USE AS TRANSPORT ENHANCER**

(57) Abstract: The present invention relates to a conjugate that comprises a) at least one compound to be delivered into or across a biological barrier, b) a delivery-enhancing transporter comprising at least 4 β-homolysine residues, especially between 4 and 25 β-homolysine residues, c) optionally a linker between the components a) and b), and d) optionally a labelling unit; to the salts of such conjugates; to a pharmaceutical composition comprising said conjugate; to a method for delivery of a compound into or across a biological barrier, the method comprising contacting the barrier with said conjugate; and to a process for the preparation of certain conjugates.